Cytomegalovirus reactivation in patients diagnosed with severe COVID-19 : A point prevalence study in a general hospital
©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/)..
OBJECTIVE: To determine the prevalence of CMV reactivation in a population admitted for severe COVID-19 to a general hospital.
METHODS: Point prevalence study in all hospitalized patients with severe COVID-19 (admitted either to general wards or ICU). Determination of the presence of CMV DNA in circulating blood. COVID-19 was confirmed in patients with compatible clinical manifestations, usually with pneumonia and a positive nasopharyngeal PCR test.
RESULTS: We included 140 hospitalized patients with COVID-19 who consented to participate. A total of 16 patients (11.42%), had circulating CMV-DNA in peripheral blood at the time of the study. Patients with positive CMV viral load were mainly ICU patients (11/37 -29,7%) and only 5/103 cases (4,85%) were hospitalized into general wards. The accumulated doses of corticosteroids (prednisone equivalents) in the study day were (median and IQR) 987.50 mg (396.87-2,454.68) and 187.50 mg (75.00-818.12) respectively in CMV positive and negative patients (p < 0.001). A significant proportion of CMV positive patients were discovered because of the study and were clinically unsuspected by their physicians. The coinfected COVID-CMV positive population had a higher risk of accumulated secondary nosocomially-acquired infections and a worse prognosis.
CONCLUSIONS: CMV reactivation should be systematically searched in patients in COVID-19 cases admitted to the ICU.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia - 36(2023), 1 vom: 21. Feb., Seite 45-51 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pérez-Granda, M J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CMV |
|---|
| Anmerkungen: |
Date Completed 24.01.2023 Date Revised 17.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.37201/req/068.2022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349221650 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349221650 | ||
| 003 | DE-627 | ||
| 005 | 20231226042117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.37201/req/068.2022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1164.xml |
| 035 | |a (DE-627)NLM349221650 | ||
| 035 | |a (NLM)36408974 | ||
| 035 | |a (PII)perez22nov2022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pérez-Granda, M J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytomegalovirus reactivation in patients diagnosed with severe COVID-19 |b A point prevalence study in a general hospital |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2023 | ||
| 500 | |a Date Revised 17.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). | ||
| 520 | |a OBJECTIVE: To determine the prevalence of CMV reactivation in a population admitted for severe COVID-19 to a general hospital | ||
| 520 | |a METHODS: Point prevalence study in all hospitalized patients with severe COVID-19 (admitted either to general wards or ICU). Determination of the presence of CMV DNA in circulating blood. COVID-19 was confirmed in patients with compatible clinical manifestations, usually with pneumonia and a positive nasopharyngeal PCR test | ||
| 520 | |a RESULTS: We included 140 hospitalized patients with COVID-19 who consented to participate. A total of 16 patients (11.42%), had circulating CMV-DNA in peripheral blood at the time of the study. Patients with positive CMV viral load were mainly ICU patients (11/37 -29,7%) and only 5/103 cases (4,85%) were hospitalized into general wards. The accumulated doses of corticosteroids (prednisone equivalents) in the study day were (median and IQR) 987.50 mg (396.87-2,454.68) and 187.50 mg (75.00-818.12) respectively in CMV positive and negative patients (p < 0.001). A significant proportion of CMV positive patients were discovered because of the study and were clinically unsuspected by their physicians. The coinfected COVID-CMV positive population had a higher risk of accumulated secondary nosocomially-acquired infections and a worse prognosis | ||
| 520 | |a CONCLUSIONS: CMV reactivation should be systematically searched in patients in COVID-19 cases admitted to the ICU | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CMV | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a coinfection | |
| 650 | 4 | |a cytomegalovirus | |
| 650 | 4 | |a nosocomial infection | |
| 700 | 1 | |a Catalán, P |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, P |e verfasserin |4 aut | |
| 700 | 1 | |a Aldámiz, T |e verfasserin |4 aut | |
| 700 | 1 | |a Barrios, J C |e verfasserin |4 aut | |
| 700 | 1 | |a Ramírez, C |e verfasserin |4 aut | |
| 700 | 1 | |a García-Martínez, R |e verfasserin |4 aut | |
| 700 | 1 | |a Villalba, M V |e verfasserin |4 aut | |
| 700 | 1 | |a Puente, L |e verfasserin |4 aut | |
| 700 | 1 | |a Bouza, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia |d 1997 |g 36(2023), 1 vom: 21. Feb., Seite 45-51 |w (DE-627)NLM090649028 |x 1988-9518 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2023 |g number:1 |g day:21 |g month:02 |g pages:45-51 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.37201/req/068.2022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2023 |e 1 |b 21 |c 02 |h 45-51 | ||